The complexity of human metastatic cancer is difficult to mimic in mouse models. As a consequence, seemingly successful studies in murine models do not translate into success in late phases of clinical trials, pouring money, time and people's hope down the drain. In 'Bedside to Bench', Isaiah Fidler and Lee Ellis discuss crucial parameters in cancer growth and therapy and emphasize the disparity between studies in humans and mice. In 'Bench to Bedside', Terry Van Dyke shows how pancreatic tumors developed de novo in the organ site in mice can explain therapy failure in people with cancer and serve as a model to test new drugs.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Preclinical evaluation of pentagamavunone-1 as monotherapy and combination therapy for pancreatic cancer in multiple xenograft models
Scientific Reports Open Access 27 December 2022
-
Resveratrol suppresses serum-induced vasculogenic mimicry through impairing the EphA2/twist-VE-cadherin/AKT pathway in human prostate cancer PC-3 cells
Scientific Reports Open Access 22 November 2022
-
Patient-derived xenograft (PDX) models, applications and challenges in cancer research
Journal of Translational Medicine Open Access 10 May 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cunningham, D. et al. Lancet 375, 1030–1047 (2010).
Hecht, J.R. et al. J. Clin. Oncol. 27, 672–680 (2009).
Tol, J. et al. N. Engl. J. Med. 360, 563–572 (2009).
Shaheen, R.M. et al. Br. J. Cancer 85, 584–589 (2001).
Saltz, L.B. et al. J. Clin. Oncol. 25, 4557–4561 (2007).
Talmadge, J.E. & Fidler, I.J. Cancer Res. 70, 5649–5669 (2010).
Blanke, C.D. et al. J. Clin. Oncol. 26, 626–632 (2008).
Heinrich, M.C. et al. J. Clin. Oncol. 21, 4342–4349 (2003).
Kobayashi, S. et al. N. Engl. J. Med. 352, 786–792 (2005).
Paez, J.G. et al. Science 304, 1497–1500 (2004).
Sjöblom, T. et al. Science 314, 268–274 (2006).
Langley, R.R. & Fidler, I.J. Endocr. Rev. 28, 297–321 (2007).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
L.M.S. is a consultant for Schering Plough. He performs ad hoc consulting for Genentech/Roche, Astra Zeneca, Regeneron and Pfizer.
Rights and permissions
About this article
Cite this article
Ellis, L., Fidler, I. Finding the tumor copycat: Therapy fails, patients don't. Nat Med 16, 974–975 (2010). https://doi.org/10.1038/nm0910-974
Issue Date:
DOI: https://doi.org/10.1038/nm0910-974
This article is cited by
-
Patient-derived xenograft (PDX) models, applications and challenges in cancer research
Journal of Translational Medicine (2022)
-
Resveratrol suppresses serum-induced vasculogenic mimicry through impairing the EphA2/twist-VE-cadherin/AKT pathway in human prostate cancer PC-3 cells
Scientific Reports (2022)
-
Preclinical evaluation of pentagamavunone-1 as monotherapy and combination therapy for pancreatic cancer in multiple xenograft models
Scientific Reports (2022)
-
Thrombin is a therapeutic target for non-small-cell lung cancer to inhibit vasculogenic mimicry formation
Signal Transduction and Targeted Therapy (2020)
-
VE-cadherin promotes vasculogenic mimicry by modulating kaiso-dependent gene expression
Cell Death & Differentiation (2019)